Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Core Insights - Clearmind Medicine Inc. has successfully completed treatment and follow-up for 18 participants in its FDA-approved Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic oral drug candidate aimed at treating Alcohol Use Disorder (AUD) [1][2][3] - The trial is progressing positively, with four additional participants treated at the Tel Aviv clinical site, indicating strong operational capabilities [2][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing non-hallucinogenic, neuroplastogen-derived therapeutics to address significant health issues, including AUD [4] - The company aims to research and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements [4] Intellectual Property - Clearmind's intellectual property portfolio includes 19 patent families and 31 granted patents, with plans to seek additional patents as necessary [5]